co-GLP-1/GIP agonist peptide (Eli lilly)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameco-GLP-1/GIP agonist peptide (Eli lilly)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucose-Dependent Insulinotropic Polypeptide Receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide Receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A